Terapias dirigidas en combinación con hormonoterapia en cáncer de mama avanzado HER2- negativo - page 7

Receptor Tyrosine Kinase

PI3K

mTORC2

mTORC1

S6K

AKT

IRS1

Growth factors

TSC

PTEN

Targeting the PI3K/mTOR

Pathway

RAD001

BKM120

BYL719

α-specific PI3K inhibitor

Pan Class I PI3K inhibitor

mTOR inhibitor

4EBP1

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6 8,9,10,11,12,13,14,15,16,17,...45